Acurx Pharmaceuticals, Inc.
ACXP · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.04 | -1.15 | 0.34 | -0.02 |
| FCF Yield | -74.90% | -20.19% | -17.52% | -11.36% |
| EV / EBITDA | -0.72 | -2.82 | -2.81 | -2.45 |
| Quality | ||||
| ROIC | -2,292.74% | -312.38% | -165.31% | -103.26% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.74 | 0.67 | 0.62 | 0.39 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | – | – |
| Free Cash Flow Growth | -5.94% | -29.95% | -50.43% | -49.59% |
| Safety | ||||
| Net Debt / EBITDA | 0.26 | 0.51 | 0.75 | 1.02 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | 0.00 |